Luteinizing Hormone ELISA Kit

Produktnummer ABIN577071

Das Human Luteinizing Hormone ELISA Kit (ABIN577071) ist ein Colorimetric ELISA Kit zur Detektion von Human Luteinizing Hormone.

Kurzübersicht für Luteinizing Hormone ELISA Kit (ABIN577071)

Target: Luteinizing Hormone (LH)

Reaktivität: Human

Nachweismethode: Colorimetric

Methodentyp: Sandwich ELISA

Applikation: ELISA

Produktdetails Luteinizing Hormone ELISA Kit

Verwendungszweck: This LH enzyme linked immunosorbent assay (ELISA) applies a technique called a quantitative sandwich immunoassay. The microtiter plate provided in this kit has been pre- coated with a monoclonal antibody specific for LH. Standards or samples are then added to the microtiter plate wells and LH if present, will bind to the antibody pre-coated on the wells. In order to quantitate the amount of LH present in the sample, a standardized preparation of horseradish peroxidase (HRP)-conjugated polyclonal antibody, specific for LH are added to each well to

Analytische Methode: Quantitative

Sensitivität: The minimal detectable concentration of LH by this assay is estimated to be 3 mIU/ml.

Bestandteile: Standards: 1 set/2 vials

Anwendungsinformationen

Plattentyp: Pre-coated

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konservierungsmittel: Without preservative

Details zu Luteinizing Hormone

Target: Luteinizing Hormone (LH)

Substanzklasse: Hormone

Hintergrund: Prostate-Specific Antigen (PSA) is a single-chain glycoprotein weighing approximately 34 kDa1. PSA is a secretion of the prostate epithelium produced by normal, benign, and cancerous cells2. PSA is functionally and immuno-chemically distinct from Prostatic Acid Phosphatase. Development of an enzyme immunoassay3 has made it possible to accurately detect low concentrations of PSA in the blood of patients with malignant and benign prostate disease. PSA serum levels are elevated in patients with prostate cancer, benign prostatic hypertrophy (BPH) and inflammatory conditions associated with the surgical stage and metastasis of the disease. After several years of clinical use, PSA has emerged as the choice overall serum marker for prostate cancer. Furthermore, numerous investigators consider S P A to be the most useful and meaningful tumour marker in cancer biology2,4. PSA is a useful serum marker for prostate cancer and represents a valuable new tool for the clinician. When used in combination with the digital rectal exam and/or transrectal ultrasound, PSA may assist in early detection programs for prostate cancer. Additionally, costly and time-consuming bone scans can be avoided for patients with newly diagnosed and untreated prostate cancer. The latter assumes a negative bone scan and therefore, a staging bone scintigram may not be necessary. Finally, an ultra- sensitive PSA assay would be useful when monitoring patients for residual disease following radical r p ostatectomy, as well as earlier detection of recurrent active disease following such therapies